RegentAtlantic Capital’s Maravai LifeSciences MRVI Stock Holding History

RegentAtlantic Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$227K	Sell	8,897 -1,349	-13%	-$33.8K	0.01%	613
2022 Q2	$291K	Hold	10,246	–	–	0.01%	553
2022 Q1	$361K	Sell	10,246 -128	-1%	-$4.29K	0.01%	535
2021 Q4	$435K	Buy	10,374 +3,989	+62%	+$162K	0.01%	479
2021 Q3	$313K	Buy	+6,385	New	+$311K	0.01%	549

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

RegentAtlantic Capital's MRVI Position: Q3 2022 in Review

RegentAtlantic Capital reduced its Maravai LifeSciences (MRVI) stake by 13% in Q3 2022, selling an estimated $33.8K and leaving 8,897 shares worth $227K. The position accounts for 0.01% of the portfolio, ranked #613.

RegentAtlantic Capital first reported a position in MRVI in Q3 2021 and has held it in 5 quarters since. The position peaked at $435K in Q4 2021. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2022.

RegentAtlantic Capital held 8,897 shares of Maravai LifeSciences worth $227K as of Q3 2022.
RegentAtlantic Capital sold 1,349 Maravai LifeSciences shares in Q3 2022, an estimated $33.8K.
Maravai LifeSciences made up 0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #613 holding.
RegentAtlantic Capital first reported a position in Maravai LifeSciences in Q3 2021 and has held it in 5 quarters since.
RegentAtlantic Capital's Maravai LifeSciences position peaked at $435K in Q4 2021.
202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.